Read this before you buy anything
ARA-290 must be reconstituted with Buffered Phosphate Solution (pH 7.4), at room temperature.
This is not optional and it is not the same as bacteriostatic water. ARA-290 is more delicate than typical peptides and degrades with improper pH or handling. Reconstitute it with the wrong solution and you have wasted the vial.
You need to purchase the buffered pH water separately. Here is one example.
Refrigerate after mixing.
A client experience with ARA-290 and SS-31
One client who had been exploring support for diabetic side effects, peripheral neuropathy, and low energy experimented with drawing ARA-290 and SS-31 into the same syringe. They reported that pairing SS-31 with ARA-290 helped lessen the injection discomfort they experienced with ARA-290, and they valued the combination because SS-31 is used in the context of mitochondrial health.
| Peptide: | ARA-290 10 mg |
| Rehydrate with: | 200 units (2 cc) Buffered Phosphate Solution (pH 7.4) Reconstitute at room temperature. ARA-290 is pH- and temperature-sensitive. Refrigerate after mixing. |
| Doses: | 8 per Vial |
| Dosage: | (25 ticks) 1.25 mg daily Give subcutaneously Typical cycle: 4–8 weeks Reassess after cycle completion |
| Benefits | Supports nerve repair and regeneration, reduces neuroinflammation, may improve small fiber density, modulates immune signaling without increasing hematocrit |
| Possible Side Effects: | Generally well tolerated, Mild injection site irritation, Occasional headache |
Please purchase your own Buffered pH water separately. Here is one example: https://www.amazon.com/gp/product/B0BY2H1LQR
Never used peptides before? Check out our video on how to do injections safely - scroll to the bottom of the page. https://www.vigeohealth.net/peptides
*Peptides sold outside of compounding pharmacies are required to be sold as "Not For Human Consumption and For Research Use Only." However, they are the exact same product as sold in compounding pharmacies, always 3rd party tested for quality, purity, and content.
If you would like to see testing results from your vendor, please ask!
If test results are not available, consider going to someone who can provide testing results for each batch!
What is ARA-290?
An erythropoietin-derived peptide, sometimes called cibinetide. It was developed specifically to separate the tissue-protective effects of EPO from its effect on red blood cell production.
That separation is the point. It modulates immune signalling and supports nerve repair without increasing hematocrit, which is what makes it usable where EPO itself would not be.
What is it studied for?
- Supports nerve repair and regeneration
- Reduces neuroinflammation
- May improve small fiber density
- Modulates immune signalling without increasing hematocrit
The tags on Dawn's original post point at the two use cases people come for: peripheral neuropathy and diabetes.
Where this connects to the mineral work
Small fiber neuropathy is the exact symptom picture covered in Part 8 of the chelation series: burning feet, buzzing, patches of numbness, sensations that are hard to describe.
That article makes the case that mercury disrupts thiamine-dependent enzymes so nerves cannot metabolise fuel properly. ARA-290 approaches the same territory from a different angle: supporting repair and reducing neuroinflammation.
Neither is a substitute for finding out what is causing it. Diabetes, B12 deficiency, thyroid dysfunction and compression are all more common causes of neuropathy than anything discussed here, and all need ruling out with a physician first.
Side effects
Generally well tolerated. Mild injection site irritation. Occasional headache.
Do your own research.
Sourcing and quality
Peptides sold outside compounding pharmacies are labelled "Not For Human Consumption and For Research Use Only." Always ask for batch-specific third-party testing. If it is not available, go elsewhere.
VIGEO Health does not sell injectable peptides. Third-party vendors can be recommended on request: email dawn@vigeohealth.net.
Test your foundations first
Nerve repair runs on thiamine, B12, magnesium and the enzymes they activate. ARA-290 signals for repair; those are the materials repair is built from.
There is a second reason to test here. If a metal burden is what is interfering with nerve metabolism in the first place, supporting repair while the interference continues is working against a headwind.
See what the OligoScan measures
What this page does not tell you
- ARA-290 is not an approved medication. It is investigational, sold as a research compound.
- Neuropathy requires diagnosis first. Diabetes, B12 deficiency, thyroid disease, spinal compression and medication effects are all more common causes and several need prompt treatment.
- Diabetics should involve their physician, both because neuropathy management is part of diabetes care and because nothing here replaces glycaemic control.
- Clinical trial data exists but is limited, mostly in sarcoidosis-related small fiber neuropathy and diabetic neuropathy.
- Long-term safety data does not exist.
References and further reading
- Clinical literature on cibinetide (ARA-290) in small fiber neuropathy.
- Research on the innate repair receptor and separation of tissue-protective from erythropoietic EPO effects.
- VIGEO Health Medical Disclaimer
Related
Questions and Answers
Q: How is ARA-290 dosed? A: 1.25 mg daily, given subcutaneously, which is 25 ticks on an insulin syringe. A 10 mg vial reconstituted with 200 units of buffered phosphate solution provides 8 doses. The typical cycle is four to eight weeks, after which the response is reassessed.
Q: What do you reconstitute ARA-290 with? A: Buffered Phosphate Solution at pH 7.4, at room temperature, not bacteriostatic water. ARA-290 is more delicate than typical peptides and degrades with improper pH or handling. It is both pH and temperature sensitive, and should be refrigerated after mixing.
Q: What is ARA-290 used for? A: It supports nerve repair and regeneration, reduces neuroinflammation, and may improve small fiber density. It modulates immune signalling without increasing hematocrit, which distinguishes it from erythropoietin itself. The main interest is in peripheral and small fiber neuropathy, including in diabetes.